The trial from Brazil may not be quickly theorized to other regions, but it begins to fill a largely uninhabited evidence base for patients not well represented in major trials of nonvalvular AF DOACs. Medscape Medical News
Learn More
RIVER: Rivaroxaban Rivals Warfarin in AF, Mitral Bioprosthesis
Byindianadmin
Nov 16, 2020